This systematic review summarize and re-assess the data of previous studies and explore early higher achieved MAP for clinical outcome after CA. The result showed that early higher achieved MAP is not associated with clinical outcome after CA.
Jakkula et al.[6] reported that early higher achieved MAP did not affect the serum concentration of neuron-specific enolase, S100B protein, cardiac troponin, regional frontal cerebral oxygenation, and epileptic activity on the electroencephalography. Ameloot et al.[16] did not find the benefits of a higher MAP target assessed by magnetic resonance imaging of the cerebrum. Compared with the standard MAP regimen, targeting high MAP in the first hours of an experimental ECPR model did not result in any hemodynamic improvement nor in a decrease in the amount of infused fluid.[17] These studies suggest that higher achieved MAP do not improve clinical outcomes after CA.
Cerebral perfusion pressure (CPP) is the driving force for cerebral blood flow. CPP is defined as the difference between MAP and intracranial pressure. However, higher MAP induced by vasoconstrictors may impair regional organ perfusion, which might be undetected when monitoring arterial pressure alone. Holmgaard et al.[18] reported that higher MAP induced by vasopressors led to lower mean regional cerebral oxygenation and more frequent and pronounced cerebral desaturation during cardiopulmonary bypass. Kisser et al.[19] reported relative ratios of cerebral blood flow in the left dorsolateral and orbital prefrontal cortex and the left temporal cortex decreased with increasing systolic blood pressure; cerebral blood flow also decreased in the left dorsolateral prefrontal cortex with increasing DBP. Under brain injury, cerebral blood flow autoregulation plateau to the left and allow lower MAP, and increasing MAP with the application of vasopressor agents might be potentially harmful if the patient exceeds the upper limit pressure of autoregulation.[20, 21]
Grand et al.[4, 22] observed a trend toward preserved renal function in the high MAP group, as illustrated by a trend towards higher eGFR and less need for renal replacement therapy in the high MAP target group. Early higher achieved MAP increased the urine volume and reduced the use of diuretics for pulmonary edema. This finding indicated that different organs may need different blood pressure levels after CA.
Identifying the optimal MAP for the overall patient population may be complicated by individual patient variability because baseline blood pressure varies among patients. Roberts et al.[10] reported that the association between MAP greater than 90 mmHg and good neurologic outcome was found to be stronger among subjects with a previous diagnosis of hypertension compared with those without hypertension. In the absence of definitive data, the European Resuscitation Council guidelines recommend targeting MAP that achieves adequate urine output (1 ml/kg/hour) and normalization or downtrend in plasma lactate.
This meta-analysis has several important limitations. First, a recognized limitation of our study is the obvious heterogeneity with regard to the baseline characteristics of the participants, study-specific resuscitation protocols, definition of the outcomes, and follow up duration. Second, most of the included studies were non-randomized controlled trials at risk of bias, particularly confounding and selection bias. Lastly, we were not able to assess publication bias or perform meta-regression due to the low number of the included articles.